Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer

Sanjay Dhar, Rohit Bhargava, Michael Yunes, Biao Li, Jaya Goyal, Stephen P. Naber, David E. Wazer, Vimla Band

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Purpose: Normal epithelial cell specific-1 (NES1)/kallikrein 10 gene is expressed in normal mammary and prostate epithelial cells, but the expression of NES1 mRNA and protein is markedly reduced in established breast and prostate cancer cell lines although the NES1 gene is intact. Here, we wished to assess whether NES1 expression is down-regulated in primary breast cancers. Experimental Design: We developed and used an in situ hybridization technique with an antisense NES1 probe to detect NES1 mRNA in sections of normal breast specimens, typical and atypical ductal hyperplasia, ductal carcinoma in situ, and infiltrating ductal carcinoma. Results: All of the 30 normal breast specimens showed high NES1 expression. Notably, 18 (75%) of 24 typical and atypical breast hyperplasia specimens showed high NES1 expression, with weak-to-moderate expression in 6 (25%). Significantly, 13 (46%) of 28 ductal carcinoma in situ specimens lacked NES1 expression, and the remaining 15 (54%) showed weak-to-moderate expression. Finally, 29 of 30 (97%) infiltrating ductal carcinoma grades I-III samples lacked NES1 mRNA, with weak expression in the remaining one sample. Conclusions: Our results demonstrate that NES1 mRNA is expressed in normal breast tissue and benign lesions, with loss of NES1 expression during tumor progression. We suggest that NES1 expression may serve as a molecular tool in the study of breast cancer progression. Studies with larger series of specimens should help assess whether NES1 expression can be a diagnostic and/or prognostic marker in breast and other cancers.

Original languageEnglish (US)
Pages (from-to)3393-3398
Number of pages6
JournalClinical Cancer Research
Volume7
Issue number11
StatePublished - Jan 1 2001

Fingerprint

Tissue Kallikreins
In Situ Hybridization
Epithelial Cells
Breast Neoplasms
Messenger RNA
Breast
Carcinoma, Intraductal, Noninfiltrating
Ductal Carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. / Dhar, Sanjay; Bhargava, Rohit; Yunes, Michael; Li, Biao; Goyal, Jaya; Naber, Stephen P.; Wazer, David E.; Band, Vimla.

In: Clinical Cancer Research, Vol. 7, No. 11, 01.01.2001, p. 3393-3398.

Research output: Contribution to journalArticle

Dhar, Sanjay ; Bhargava, Rohit ; Yunes, Michael ; Li, Biao ; Goyal, Jaya ; Naber, Stephen P. ; Wazer, David E. ; Band, Vimla. / Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. In: Clinical Cancer Research. 2001 ; Vol. 7, No. 11. pp. 3393-3398.
@article{16ba09d60e264b2c985cc312b7710a2a,
title = "Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer",
abstract = "Purpose: Normal epithelial cell specific-1 (NES1)/kallikrein 10 gene is expressed in normal mammary and prostate epithelial cells, but the expression of NES1 mRNA and protein is markedly reduced in established breast and prostate cancer cell lines although the NES1 gene is intact. Here, we wished to assess whether NES1 expression is down-regulated in primary breast cancers. Experimental Design: We developed and used an in situ hybridization technique with an antisense NES1 probe to detect NES1 mRNA in sections of normal breast specimens, typical and atypical ductal hyperplasia, ductal carcinoma in situ, and infiltrating ductal carcinoma. Results: All of the 30 normal breast specimens showed high NES1 expression. Notably, 18 (75{\%}) of 24 typical and atypical breast hyperplasia specimens showed high NES1 expression, with weak-to-moderate expression in 6 (25{\%}). Significantly, 13 (46{\%}) of 28 ductal carcinoma in situ specimens lacked NES1 expression, and the remaining 15 (54{\%}) showed weak-to-moderate expression. Finally, 29 of 30 (97{\%}) infiltrating ductal carcinoma grades I-III samples lacked NES1 mRNA, with weak expression in the remaining one sample. Conclusions: Our results demonstrate that NES1 mRNA is expressed in normal breast tissue and benign lesions, with loss of NES1 expression during tumor progression. We suggest that NES1 expression may serve as a molecular tool in the study of breast cancer progression. Studies with larger series of specimens should help assess whether NES1 expression can be a diagnostic and/or prognostic marker in breast and other cancers.",
author = "Sanjay Dhar and Rohit Bhargava and Michael Yunes and Biao Li and Jaya Goyal and Naber, {Stephen P.} and Wazer, {David E.} and Vimla Band",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "7",
pages = "3393--3398",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer

AU - Dhar, Sanjay

AU - Bhargava, Rohit

AU - Yunes, Michael

AU - Li, Biao

AU - Goyal, Jaya

AU - Naber, Stephen P.

AU - Wazer, David E.

AU - Band, Vimla

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Purpose: Normal epithelial cell specific-1 (NES1)/kallikrein 10 gene is expressed in normal mammary and prostate epithelial cells, but the expression of NES1 mRNA and protein is markedly reduced in established breast and prostate cancer cell lines although the NES1 gene is intact. Here, we wished to assess whether NES1 expression is down-regulated in primary breast cancers. Experimental Design: We developed and used an in situ hybridization technique with an antisense NES1 probe to detect NES1 mRNA in sections of normal breast specimens, typical and atypical ductal hyperplasia, ductal carcinoma in situ, and infiltrating ductal carcinoma. Results: All of the 30 normal breast specimens showed high NES1 expression. Notably, 18 (75%) of 24 typical and atypical breast hyperplasia specimens showed high NES1 expression, with weak-to-moderate expression in 6 (25%). Significantly, 13 (46%) of 28 ductal carcinoma in situ specimens lacked NES1 expression, and the remaining 15 (54%) showed weak-to-moderate expression. Finally, 29 of 30 (97%) infiltrating ductal carcinoma grades I-III samples lacked NES1 mRNA, with weak expression in the remaining one sample. Conclusions: Our results demonstrate that NES1 mRNA is expressed in normal breast tissue and benign lesions, with loss of NES1 expression during tumor progression. We suggest that NES1 expression may serve as a molecular tool in the study of breast cancer progression. Studies with larger series of specimens should help assess whether NES1 expression can be a diagnostic and/or prognostic marker in breast and other cancers.

AB - Purpose: Normal epithelial cell specific-1 (NES1)/kallikrein 10 gene is expressed in normal mammary and prostate epithelial cells, but the expression of NES1 mRNA and protein is markedly reduced in established breast and prostate cancer cell lines although the NES1 gene is intact. Here, we wished to assess whether NES1 expression is down-regulated in primary breast cancers. Experimental Design: We developed and used an in situ hybridization technique with an antisense NES1 probe to detect NES1 mRNA in sections of normal breast specimens, typical and atypical ductal hyperplasia, ductal carcinoma in situ, and infiltrating ductal carcinoma. Results: All of the 30 normal breast specimens showed high NES1 expression. Notably, 18 (75%) of 24 typical and atypical breast hyperplasia specimens showed high NES1 expression, with weak-to-moderate expression in 6 (25%). Significantly, 13 (46%) of 28 ductal carcinoma in situ specimens lacked NES1 expression, and the remaining 15 (54%) showed weak-to-moderate expression. Finally, 29 of 30 (97%) infiltrating ductal carcinoma grades I-III samples lacked NES1 mRNA, with weak expression in the remaining one sample. Conclusions: Our results demonstrate that NES1 mRNA is expressed in normal breast tissue and benign lesions, with loss of NES1 expression during tumor progression. We suggest that NES1 expression may serve as a molecular tool in the study of breast cancer progression. Studies with larger series of specimens should help assess whether NES1 expression can be a diagnostic and/or prognostic marker in breast and other cancers.

UR - http://www.scopus.com/inward/record.url?scp=0035187307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035187307&partnerID=8YFLogxK

M3 - Article

C2 - 11705853

AN - SCOPUS:0035187307

VL - 7

SP - 3393

EP - 3398

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -